⏳ Fetching live dividend data...
Home › Calculator › ORTX Dividend Calculator 2026
Orchard Therapeutics plc · NASDAQ
Price: $16.70 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in ORTX → $31.0K in 10 years · $276.22/month
Orchard Therapeutics plc is a biopharmaceutical firm dedicated to developing gene-based treatments for severe and often fatal rare conditions, operating across the United Kingdom, European Union, and the United States. Their innovative gene therapy strategy involves modifying a patient's own hematopoietic stem cells, converting them into a therapeutic cellular drug that can address the illness with just one dose. The company markets Strimvelis, a gammaretroviral therapy approved for treating adenosine deaminase-severe combined immunodeficiency (ADA-SCID). Orchard's clinical pipeline features several investigational therapies, including OTL-101 for ADA-SCID, OTL-200 targeting metachromatic leukodystrophy, OTL-103 for Wiskott-Aldrich syndrome, OTL-102 for X-linked chronic granulomatous disease, and OTL-300 for transfusion-dependent beta-thalassemia. Early-stage research programs encompass OTL-203 for mucopolysaccharidosis type I, OTL-201 for MPS-IIIA, and OTL-202 for MPS IIIB. Furthermore, a strategic partnership with Pharming Group N.V. covers the research, development, production, and commercialization of OTL-105, an experimental ex vivo autologous hematopoietic stem cell gene therapy designed for hereditary angioedema. Established in 2015 as Orchard Rx Limited, Orchard Therapeutics plc is headquartered in London, UK.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open ORTX position with:
Real after-tax yield depends on where you live and how you hold ORTX.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 11.98% | 9.18% | $1,198 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 10.18% | 7.38% | $1,018 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 9.58% | 6.78% | $958 / yr |
| 🇬🇧 UK ISA | 0% | 11.98% | 9.18% | $1,198 / yr |
| 🇬🇧 UK Taxable | 8.75% | 10.93% | 8.13% | $1,093 / yr |
| 🇨🇦 TFSA | 0% | 11.98% | 9.18% | $1,198 / yr |
| 🇨🇦 CA Taxable | 25% | 8.98% | 6.18% | $899 / yr |
| 🇦🇺 Super (pension) | 15% | 10.18% | 7.38% | $1,018 / yr |
| 🇦🇺 AU Taxable | 30% | 8.39% | 5.59% | $839 / yr |
| 🇩🇪 DE Taxable | 26.375% | 8.82% | 6.02% | $882 / yr |
| 🇫🇷 FR Taxable | 30% | 8.39% | 5.59% | $839 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
ORTX pays quarterly — 4 times per year. Next ex-div: TBD.
How ORTX compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for ORTX sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| D-Return | 2024-01-24 | 46,000 | $0.47 | $21.9K | ||
| D-Return | 2024-01-24 | 105,000 | $0.49 | $52.0K | ||
| D-Return | 2024-01-24 | 46,000 | $0.47 | $21.9K | ||
| D-Return | 2024-01-24 | 105,000 | $0.49 | $52.0K | ||
| D-Return | 2024-01-24 | 44,391 | $16.00 | $710.3K | ||
| D-Return | 2024-01-24 | 335,000 | $0.46 | $153.8K | ||
| D-Return | 2024-01-24 | 405,590 | $0.46 | $188.2K | ||
| D-Return | 2024-01-24 | 179,390 | $0.58 | $104.0K | ||
| D-Return | 2024-01-24 | 92,081 | $16.00 | $1.47M | ||
| D-Return | 2024-01-24 | 46,000 | $0.47 | $21.9K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Revenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the ORTX dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Orchard Therapeutics plc (ORTX) is currently trading at $16.70, 77% below its 52-week high. The current dividend yield is 11.98% based on an annual payout of $2.00 per share.
Orchard Therapeutics plc (ORTX) is a healthcare stock currently trading at $16.70 with a dividend yield of 11.98%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.
⏱️ Takes 30 seconds · No signup · Free forever